NASDAQ:AVIR

Atea Pharmaceuticals (AVIR) Stock Forecast, Price & News

$3.20

+0.02 (+0.63%)

(As of 09/22/2023 ET)

Compare

Today's Range: $3.18
▼
$3.24
50-Day Range: $3.18
▼
$3.79
52-Week Range: $2.94
▼
$6.32

Volume: 252,306 shs
Average Volume: 378,544 shs
Market Capitalization: $266.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Atea Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Sell
1.33 Rating Score
Upside/Downside: 87.5% Upside
$6.00 Price Target
Short Interest: Bearish
2.41% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.80) to ($2.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

Medical Sector

874th out of 963 stocks

Pharmaceutical Preparations Industry

420th out of 458 stocks

2.7

Analyst's Opinion

Consensus Rating
Atea Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no buy ratings, 1 hold rating, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Atea Pharmaceuticals has a forecasted upside of 87.5% from its current price of $3.20.
Amount of Analyst Coverage
Atea Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.41% of the float of Atea Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Atea Pharmaceuticals has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Atea Pharmaceuticals has recently increased by 4.73%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Atea Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Atea Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AVIR.

0.6

News and Social Media Coverage

MarketBeat Follows
3 people have added Atea Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atea Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.50% of the stock of Atea Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
72.10% of the stock of Atea Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Atea Pharmaceuticals are expected to decrease in the coming year, from ($1.80) to ($2.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Atea Pharmaceuticals is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atea Pharmaceuticals is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Atea Pharmaceuticals has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Atea Pharmaceuticals (NASDAQ:AVIR) Stock

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

AVIR Price History

30 days | 90 days | 365 days | Advanced Chart

AVIR Stock News Headlines

September 6, 2023 | finance.yahoo.com

Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

August 11, 2023 | msn.com

JP Morgan Downgrades Atea Pharmaceuticals (AVIR)

September 24, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

August 9, 2023 | finance.yahoo.com

Q2 2023 Atea Pharmaceuticals Inc Earnings Call

August 8, 2023 | msn.com

Atea Pharmaceuticals GAAP EPS of -$0.34 beats by $0.15

August 8, 2023 | finance.yahoo.com

Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

August 8, 2023 | benzinga.com

Earnings Preview For Atea Pharmaceuticals

August 1, 2023 | finance.yahoo.com

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

September 24, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

July 6, 2023 | uk.finance.yahoo.com

AVIR - Atea Pharmaceuticals, Inc.

June 27, 2023 | fool.com

Atea Pharmaceuticals (NASDAQ: AVIR)

June 22, 2023 | marketwatch.com

8-K: Atea Pharmaceuticals, Inc.

June 15, 2023 | finance.yahoo.com

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

June 5, 2023 | finance.yahoo.com

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 30, 2023 | marketwatch.com

Atea Pharmaceuticals Rejects Buyout Offer

May 30, 2023 | markets.businessinsider.com

Atea Pharma Rejects Unsolicited Proposal From Tang Capital Partners

May 30, 2023 | finance.yahoo.com

Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

May 24, 2023 | finanznachrichten.de

Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners' Affiliate, Concentra Biosciences

May 23, 2023 | finance.yahoo.com

Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

May 22, 2023 | msn.com

Atea Pharmaceuticals Surges Over on Potential Takeover Bid

May 22, 2023 | msn.com

VectivBio Holding, Greenhill, Atea Pharmaceuticals And Other Big Stocks Moving Higher On Monday

May 22, 2023 | msn.com

Atea Pharmaceuticals jumps on $5.75 a share takeover offer from Tang Capital

May 10, 2023 | finance.yahoo.com

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call Transcript

May 9, 2023 | finanznachrichten.de

Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 9, 2023 | msn.com

Earnings Scheduled For May 8, 2023

May 9, 2023 | finance.yahoo.com

Q1 2023 Atea Pharmaceuticals Inc Earnings Call

May 8, 2023 | msn.com

Atea Pharmaceuticals GAAP EPS of -$0.43 beats by $0.07

See More Headlines

Receive AVIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVIR Company Calendar

Last Earnings: 8/08/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AVIR
CUSIP: N/A
CIK: 1593899
Web: www.ateapharma.com
Phone: 857-284-8891
Fax: N/A
Employees: 72
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +87.5%
Consensus Rating: Sell
Rating Score (0-4): 1.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-115,910,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -16.82%
Return on Assets: -16.22%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 38.42
Quick Ratio: 38.42

Sales & Book Value

Annual Sales: $351.37 million
Price / Sales: 0.76
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.69 per share
Price / Book: 0.42

Miscellaneous

Outstanding Shares: 83,400,000
Free Float: 71,306,000
Market Cap: $266.88 million
Optionable: Not Optionable
Beta: 0.18

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Jean-Pierre Sommadossi Ph.D. (Age 67)
Founder, Chairman, CEO & Pres
Comp: $1.1M

Ms. Andrea J. Corcoran J.D. (Age 61)
CFO, Exec. VP of Legal & Sec.
Comp: $732.45k

Mr. John F. Vavricka (Age 59)
Chief Commercial Officer
Comp: $581.11k

Dr. Janet M. J. Hammond M.D. (Age 63)
Ph.D., Chief Devel. Officer
Comp: $817.16k

Dr. Maria Arantxa Horga M.D. (Age 55)
Chief Medical Officer
Comp: $695.85k

Mr. Wayne Foster CPA (Age 54)
CPA, Exec. VP of Fin. & Chief Accounting Officer

Ms. Jonae R. Barnes
Sr. VP of Investor Relations & Corp. Communications

Mr. Ariyapadi N. Krishnaraj
VP of Marketing

Mr. Adel Moussa Ph.D.
Exec. VP of Chemistry

Mr. Xiao-Jian Zhou Ph.D.
Exec. VP of Early Stage Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AVIR Stock - Frequently Asked Questions

Should I buy or sell Atea Pharmaceuticals stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "sell" AVIR shares.
View AVIR analyst ratings or view top-rated stocks.
What is Atea Pharmaceuticals' stock price forecast for 2023?: 3 analysts have issued 1 year price targets for Atea Pharmaceuticals' shares. Their AVIR share price forecasts range from $4.00 to $8.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 87.5% from the stock's current price.
View analysts price targets for AVIR or view top-rated stocks among Wall Street analysts.
How have AVIR shares performed in 2023?: Atea Pharmaceuticals' stock was trading at $4.81 on January 1st, 2023. Since then, AVIR shares have decreased by 33.5% and is now trading at $3.20.
View the best growth stocks for 2023 here.
When is Atea Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AVIR earnings forecast.
How were Atea Pharmaceuticals' earnings last quarter?: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) announced its earnings results on Tuesday, August, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.13.
What ETFs hold Atea Pharmaceuticals' stock?: ETFs with the largest weight of Atea Pharmaceuticals (NASDAQ:AVIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and ETFMG Treatments Testing and Advancements ETF (GERM).iShares U.S. Pharmaceuticals ETF (IHE).

When did Atea Pharmaceuticals IPO?: (AVIR) raised $253 million in an initial public offering (IPO) on Friday, October 30th 2020. The company issued 11,000,000 shares at $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair served as the underwriters for the IPO.
What is Atea Pharmaceuticals' stock symbol?: Atea Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVIR."
Who are Atea Pharmaceuticals' major shareholders?: Atea Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.24%), BML Capital Management LLC (2.68%), Geode Capital Management LLC (1.97%), State Street Corp (1.84%), Renaissance Technologies LLC (1.63%) and Acadian Asset Management LLC (1.19%). Insiders that own company stock include Franklin M Berger and Polly A Murphy.
View institutional ownership trends.
How do I buy shares of Atea Pharmaceuticals?: Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Atea Pharmaceuticals' stock price today?: One share of AVIR stock can currently be purchased for approximately $3.20.
How much money does Atea Pharmaceuticals make?: Atea Pharmaceuticals (NASDAQ:AVIR) has a market capitalization of $266.88 million and generates $351.37 million in revenue each year. The company earns $-115,910,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.
How can I contact Atea Pharmaceuticals?: The official website for the company is www.ateapharma.com. The company can be reached via phone at 857-284-8891 or via email at investors@ateapharma.com.

This page (NASDAQ:AVIR) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Atea Pharmaceuticals (AVIR) Stock Forecast, Price & News

Atea Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Atea Pharmaceuticals (NASDAQ:AVIR) Stock

AVIR Price History

AVIR Stock News Headlines

AVIR Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AVIR Stock - Frequently Asked Questions

Overall MarketRank^™